These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11918519)

  • 1. Potential use of HMG-CoA reductase inhibitors for osteoporosis.
    Cushenberry LM; de Bittner MR
    Ann Pharmacother; 2002 Apr; 36(4):671-8. PubMed ID: 11918519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management.
    Coons JC
    Ann Pharmacother; 2002 Feb; 36(2):326-30. PubMed ID: 11847956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture?
    Schlienger RG; Meier CR
    Drugs Aging; 2003; 20(5):321-36. PubMed ID: 12696993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins and osteoporosis: new role for old drugs.
    Jadhav SB; Jain GK
    J Pharm Pharmacol; 2006 Jan; 58(1):3-18. PubMed ID: 16393459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis.
    Hatzigeorgiou C; Jackson JL
    Osteoporos Int; 2005 Aug; 16(8):990-8. PubMed ID: 15744453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
    Duplaga BA
    Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG CoA reductase inhibitors and the skeleton: a comprehensive review.
    Bauer DC
    Osteoporos Int; 2003 Jun; 14(4):273-82. PubMed ID: 12736772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins and osteoporosis: a clinical review.
    Gonyeau MJ
    Pharmacotherapy; 2005 Feb; 25(2):228-43. PubMed ID: 15767237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal effects of statins.
    Yaturu S
    Endocr Pract; 2003; 9(4):315-20. PubMed ID: 14561578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia.
    Waldman A; Kritharides L
    Drugs; 2003; 63(2):139-52. PubMed ID: 12515562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
    Tzefos M; Olin JL
    J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Statins as a new therapeutic possibility in osteoporosis? Wishful thinking as opposed to data].
    Barthel HR
    Dtsch Med Wochenschr; 2001 Oct; 126(42):1189-90. PubMed ID: 11607863
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials.
    Bauer DC; Mundy GR; Jamal SA; Black DM; Cauley JA; Ensrud KE; van der Klift M; Pols HA
    Arch Intern Med; 2004 Jan; 164(2):146-52. PubMed ID: 14744837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction.
    Metz CA; Lucas KH
    Ann Pharmacother; 2001 Apr; 35(4):496-500. PubMed ID: 11302415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
    Prescott WA; Streetman DA; Streetman DS
    Ann Pharmacother; 2004 Dec; 38(12):2105-14. PubMed ID: 15507504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitavastatin: a new HMG-CoA reductase inhibitor.
    Wensel TM; Waldrop BA; Wensel B
    Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of HMG-CoA reductase inhibitors in treating osteoporosis.
    Richard AA; Harrison TM
    Am J Health Syst Pharm; 2002 Feb; 59(4):372-7. PubMed ID: 11885403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.